← Back

Brangista, Inc.

Brangista Inc. produces and publishes e-magazines, primarily in Japan. It operates through three segments: Promotion Support, Media, and Solutions. The Promotion Support business offers promotional tools that let users use photos and videos of famous talents for a fixed monthly fee. The Media Business publishes e-magazines such as Tabiiro, a travel e-magazine, and operates TravelNote, which provides information on domestic and overseas travel, tourist spots, restaurants, and hotels, and also offers services such as advertising in electronic magazines and commissioned production of electronic magazines. The Solutions Business provides website creation and operation services, along with consulting, page creation, analysis, and promotion services, including solutions for Japanese and local companies operating in Taiwan. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.

Country
Price · split & dividend adjusted
News & notes moving 6176.JP
Japan
6176.JP▲

gumi Rises for First Time in Three Days, Stimulated by SBI's Additional Acquisition of Brangista

gumi rose for the first time in three days. The previous day, September 3, SBI Holdings announced that it would acquire additional shares of Brangista through its subsidiary SBINM to strengthen business consolidation, and expectations are growing that this could also be a tailwind for gumi, which is also advancing business collaboration with the SBI Group. Meanwhile, Brangista saw a rush of buying from the morning and was indicated at its limit-up price.
Brangista, Inc. ▲gumi, Inc. ▲SBI Holdings I… ▲
6176.JP · Capital · Positive SBI Holdings announced additional share acquisition of Brangista, driving the stock to its limit-up price.
3903.JP · Capital · Positive SBI's additional acquisition of Brangista raises expectations of a tailwind for gumi via its business collaboration with the SBI Group.
8473.JP · Capital · Positive SBI Holdings announced it will acquire additional Brangista shares through subsidiary SBINM to strengthen business consolidation.
Read original ↗
gamebiz·30dRead more →
Japan
Biotech & Genomic Medicine

Caion Signs Joint Research Agreement with FRONTEO for AI Drug Discovery

Caion has entered into a joint research agreement with FRONTEO regarding AI drug discovery. Additionally, CAPITA will record a special gain in the second quarter of the fiscal year ending March 2027 due to the sale of idle land. JMHD has revised down its consolidated earnings forecast for the fiscal year ending July 2026. Nexera has received a milestone payment of $86 million from Centessa based on progress in late-stage development. DWTi has decided on a domestic development plan for its glaucoma treatment agent H-1337. Blangista has seen additional share acquisition by SBINM LLC in connection with the strengthening of capital ties with SBI.
FRONTEO, Inc. ▲Nxera Pharma C… ▲D.Western Ther… ▲CPI.LSE ▲Brangista, Inc. CNTA ▲+1
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › AI Drug Discovery Technology
2158.JP · Technology · Positive FRONTEO signed a joint research agreement with Caion for AI drug discovery.
4565.JP · Capital · Positive Nexera received an $86 million milestone payment from Centessa based on late-stage development progress.
4576.JP · Technology · Positive DWTi decided on a domestic development plan for its glaucoma treatment agent H-1337.
CPI.LSE · Capital · Positive CAPITA will record a special gain in Q2 FY ending March 2027 from the sale of idle land.
6176.JP · Capital · Neutral SBINM LLC acquired additional Brangista shares in connection with strengthening capital ties with SBI; effect on Brangista is unclear.
CNTA · Demand · Positive Centessa paid an $86 million milestone to Nexera based on progress in late-stage development, indicating advancement of its pipeline.
Read original ↗
ウエルスアドバイザー·31dRead more →
© 2026 MarketDXAsset